SCHEMBL17360510

SCHEMBL17360510

Nc1cnc(Oc2ccc(-c3cc(Cl)cnc3N)cc2)nc1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 13/20 0.55
▸ MAP4K4 O95819 5/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ MINK1 Q8N4C8 1/20 0.44
▸ TNIK Q9UKE5 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17532997 0.83 NTRK1 (0.51) NTRK1MAP4K4MEN1KMT2A
SCHEMBL623961 0.82 MAP4K4 (0.57) NTRK1MAP4K4CYP1A2KCNH2MINK1
SCHEMBL625203 0.80 MAP4K4 (0.50) NTRK1MAP4K4CYP1A2KCNH2MINK1
SCHEMBL17360450 0.78 NTRK1 (0.73) NTRK1
SCHEMBL17360475 0.78 NTRK1 (0.73) NTRK1
SCHEMBL6509007 0.78 NPSR1 (0.57) NPSR1CYP1A2KCNH2MEN1NPC1
SCHEMBL17360185 0.77 NTRK1 (0.80) NTRK1
SCHEMBL17360302 0.77 NTRK1 (0.73) NTRK1
SCHEMBL17360092 0.77 NTRK1 (0.71) NTRK1
SCHEMBL870523 0.75 BTK (0.51) NTRK1MAP4K4CYP1A2KCNH2MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3800183-A1 UREA DERIVATIVES AS TRK-INHIBITING COMPOUNDS ONO Pharmaceutical Co., Ltd. (JP) 2021-04-07 — — EP disclosed
EP-3800183-A1 UREA DERIVATIVES AS TRK-INHIBITING COMPOUNDS ONO Pharmaceutical Co., Ltd. (JP) 2021-04-07 — — EP disclosed
EP-3459935-B1 UREA DERIVATIVE AS TRK-INHIBITING COMPOUND ONO PHARMACEUTICAL CO (JP) 2020-12-23 — — EP disclosed
US-10765676-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2020-09-08 — — US disclosed
US-10765676-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2020-09-08 — — US disclosed
US-20190231777-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2019-08-01 — — US disclosed
US-20190231777-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2019-08-01 — — US disclosed
US-10300060-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-28 — — US disclosed
US-10300060-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-28 — — US disclosed
EP-3459935-A1 TRK-INHIBITING COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2019-03-27 — — EP disclosed
US-9463192-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2016-10-11 — — US disclosed
US-9463192-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2016-10-11 — — US disclosed
US-20160280684-A1 TRK-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-09-29 — — US disclosed
US-20160280684-A1 TRK-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-09-29 — — US disclosed
US-20160280684-A1 TRK-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-09-29 — — US disclosed
US-20160000783-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-01-07 — — US disclosed
US-20160000783-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-01-07 — — US disclosed
US-20160000783-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2016-01-07 — — US disclosed
EP-2960234-A1 Trk-INHIBITING COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2015-12-30 — — EP disclosed
EP-2960234-A1 Trk-INHIBITING COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2015-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10300060-B2 Trk-inhibiting compound LTK, ROR1, TRPV1 NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885
US-20160280684-A1 TRK-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885
US-20160000783-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885
US-20190231777-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TRPV1 NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885
US-10765676-B2 Trk-inhibiting compound LTK, ROR1, TRPV1 NTRK1 33/4885MAP4K4 297/4885NPSR1 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback